Helius Medical Technologies Achieves Nasdaq Bid Price Compliance

Helius Medical Technologies ( (HSDT) ) just unveiled an update.

On June 3, 2025, Helius Medical Technologies received formal notification from Nasdaq confirming its compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. Despite this compliance, the company must still meet the equity requirement by June 30, 2025, to fulfill all Nasdaq listing criteria, keeping the Nasdaq Listing Qualifications hearing process open until then.

The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Spark’s Take on HSDT Stock

According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.

Helius Medical Technologies faces significant financial hurdles with declining revenue and consistent losses, impacting both cash flow and equity. Technical indicators show a weak momentum with a slight bearish trend. Valuation metrics reflect unprofitability, making the stock less attractive. Immediate improvements in financial performance and operational efficiency are crucial for a positive outlook.

To see Spark’s full report on HSDT stock, click here.

More about Helius Medical Technologies

Helius Medical Technologies is a leading neurotech company in the medical device field, focusing on neurologic deficits with an orally applied technology platform. This platform amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS®).

Average Trading Volume: 14,922

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.93M

See more insights into HSDT stock on TipRanks’ Stock Analysis page.